Collaborations, New Studies, and New Drug Applications - Research Report on Amgen, Gilead, Abbott, Biogen Idec, and

 Collaborations, New Studies, and New Drug Applications - Research Report on
             Amgen, Gilead, Abbott, Biogen Idec, and UnitedHealth

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 16, 2013

NEW YORK, September 16, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Amgen,
Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Abbott Laboratories
(NYSE: ABT), Biogen Idec Inc. (NASDAQ: BIIB), and UnitedHealth Group Inc.
(NYSE: UNH). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Amgen, Inc. Research Report

On September 11, 2013, Amgen, Inc. (Amgen) announced that a biomarker analysis
of Vectibix (panitumumab) in combination with FOLFOX - an oxaliplatin-based
chemotherapy, for the first time in patients with colorectal cancer (mCRC) -
was published in the New England Journal of Medicine. Amgen stated that the
analysis found that RAS mutations, beyond the known KRAS exon 2 mutations,
predict lack of response to Vectibix in combination with FOLFOX. Amgen further
informed that RAS mutations are ones found in exons 2, 3, and 4 of KRAS and
NRAS. Jean-Yves Douillard, M.D., Ph.D., Professor of Medical Oncology Centre
R. Gauducheau France and PRIME trial lead investigator and study author, said,
"While the KRAS exon 2 biomarker is well-known and has facilitated selection
of patients more likely to respond to anti-EGFR treatment. This analysis is
important as it furthers our understanding of tumor genetics and allows
physicians to more accurately match patients to effective treatments." The
Full Research Report on Amgen, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

Gilead Sciences, Inc. Research Report

On September 11, 2013, Gilead Sciences Inc. (Gilead) announced that the
Company has submitted a New Drug Application (NDA) to the US Food and Drug
Administration (FDA) for the approval of idelalisib, an investigational,
targeted, oral inhibitor of PI3K delta for the treatment of indolent
non-Hodgkin's lymphoma (iNHL). Gilead also informed that along with this NDA,
the Company submitted data that supports the use of idelalisib for patients
with iNHL that is refractory (non-responsive) to rituximab and to
alkylating-agent-containing chemotherapy. The Company further added that it
plans to file for regulatory approval of idelalisib in the European Union in
Q4 2013. The Full Research Report on Gilead Sciences, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9898_GILD]

Abbott Laboratories Research Report

On September 4, 2013, Abbott Laboratories (Abbott) announced that preliminary
results from a study evaluating Abbott's ARCHITECT STAT High Sensitive
Troponin-I (hsTnI) test, which also received CE Mark in January 2013, were
presented at the ESC Congress 2013. According to the Company, the study
suggests that Abbott's high sensitive troponin test may help doctors improve
the diagnosis and prognosis of patients presenting with symptoms of heart
attack. The Company added that the test could be particularly beneficial for
women, who may have different presenting symptoms, and are often
under-diagnosed. Abbott's researchers shared data from the first 1,126
patients of the study presenting with symptoms of a heart attack. According to
Abbott, early findings shows that women have lower peak levels of troponin
than men, resulting to the under-diagnosis and therefore under-treatment of
heart attacks for women. Abbott further informed that the ARCHITECT STAT hsTnI
assay is commercially available in Europe, as well as Canada, Australia, New
Zealand, and Brazil; however, the test is currently for research-use only in
the US. The Full Research Report on Abbott Laboratories - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05c1_ABT]

Biogen Idec Inc. Research Report

On September 9, 2013, Biogen Idec Inc. (Biogen Idec) announced that it has
entered into a broad, multi-year collaboration with Isis Pharmaceuticals, Inc.
(Isis) to leverage antisense technology to advance the treatment of
neurological diseases. According to Biogen Idec, it will gain exclusive rights
to the use of Isis' antisense technology to develop therapies for neurological
diseases as part of the six-year research collaboration. According to the
Company, the terms of the collaboration include: Biogen Idec will make an
upfront payment of $100 million, which will be reflected as R&D expense in the
Company's Q3 2013 financial results; Isis is eligible to receive milestone
payments, license fees, and royalty payments for all treatments developed
through this collaboration, with the specific amount dependent upon the
modality of the molecule advanced by Biogen Idec; and in the case of antisense
molecules, the milestone payments could be as much as $220 million, plus
additional amounts related to the cost of clinical trials conducted by Isis
under the collaboration. The Full Research Report on Biogen Idec Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b95b_BIIB]

UnitedHealth Group Inc. Research Report

On September 11, 2013, UnitedHealth Group Inc. (UnitedHealth), Quality Health
Solutions Inc. (QHS), and the Medical College of Wisconsin announced a new
accountable care initiative that will provide coordinated care to over 100,000
Wisconsin residents enrolled in UnitedHealthcare's employer-sponsored health
plans. According to the Company, the 3,000 physicians and 18 hospitals
comprising five QHS members of the southeastern Wisconsin (Agnesian
Healthcare, Columbia St. Mary's, Froedtert Health, Wheaton Franciscan
Healthcare, and the Medical College of Wisconsin) will be rewarded for
effectively managing all aspects of patients' care. In addition, QHS will
offer primary care physicians ongoing status reports on their patients,
allowing them to monitor each patient's care and maintain their clinical
information in a secure patient registry. UnitedHealth further stated that the
new initiative will go into effect on January 1, 2014. The Full Research
Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/73e5_UNH]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.